Phase 2 Dose-Finding Study of JTT-305 in Patients with Primary Osteoporosis.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220803

Enrollment

320

Registered

2009-08-14

Start date

2009-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Osteoporosis

Interventions

investigational material(s) Generic name etc : JTT-305 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - More than 5 years since menopause - < 70% of YAM at lumbar spine - < 80% of YAM at lumbar spine with one mild vertebral fracture

Exclusion criteria

Exclusion criteria: - Vertebral fractures on the 1st to 4th lumbar spine - History of drug use; 1) Strontium ranelate, anti-RANKL antibody preparations, or parathyroid hormone preparations 2) Bisphosphonates within 1 year of the screening visit

Design outcomes

Primary

Measure	Time frame
Percentile change in lumbar spine BMD	—

Secondary

Measure	Time frame
Bone turnover markers	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026